In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...